首页 > 最新文献

Journal of the Chinese Medical Association : JCMA最新文献

英文 中文
Risks of Kawasaki disease and multisystem inflammatory syndrome in pediatric patients with COVID-19 infection: A TriNetX based cohort study. 感染 COVID-19 的儿科患者发生 KD 和 MIS-C 的风险:基于 TriNetX 的队列研究。
Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCMA.0000000000001137
Kuang-Jen Chien, Cheng-Chung James Wei, Shih-Hui Huang, Chun-Yu Chen, Ho-Chang Kuo, Yao-Min Hung, Pei-Lun Liao, Jing-Yang Huang, Ming-Fang Cheng, Ken-Pen Weng

Background: The associations of coronavirus disease (COVID-19) with Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) remain unclear. Few large-scale studies have estimated the cumulative incidence of MIS-C and KD after COVID-19 in children.

Methods: Data were obtained from TriNetX. After propensity score matching was completed, data from 258 645 patients with COVID-19 (COVID-19 group) and 258 645 patients without COVID-19 (non-COVID-19 group) were analyzed using Cox regression. Hazard ratio (HR), 95% CI, and cumulative incidence of MIS-C and KD were calculated for both groups. A stratified analysis was performed to validate the results.

Results: After matching for age at baseline and sex, the risks of MIS-C and KD were higher in the COVID-19 group than in the non-COVID-19 group (HR: 3.023 [95% CI, 2.323-3.933] and 1.736 [95% CI, 1.273-2.369], respectively). After matching for age at baseline, sex, race, ethnicity, and comorbidities, the risks of MIS-C and KD remained significantly higher in the COVID-19 group than in the non-COVID-19 group (HR: 2.899 [95% CI, 2.173-3.868] and 1.435 [95% CI, 1.030-2.000]). When stratified by age, the risk of MIS-C was higher in the COVID-19 group-for patients aged >5 years and ≤5 years (HR: 2.399 [95% CI, 1.683-3.418] and 2.673 [95% CI, 1.737-4.112], respectively)-than in the non-COVID-19 group. However, the risk of KD was elevated only in patients aged ≤5 years (HR: 1.808; 95% CI, 1.203-2.716). When stratified by COVID-19 vaccination status, the risks of MIS-C and KD were elevated in unvaccinated patients with COVID-19 (HR: 2.406 and 1.835, respectively).

Conclusion: Patients with COVID-19 who are aged <18 and ≤5 years have increased risks of MIS-C and KD, respectively. Further studies are required to confirm the role of COVID-19 in the pathogenesis of MIS-C and KD.

背景:COVID-19与川崎病(KD)和儿童多系统炎症综合征(MIS-C)的关系仍不清楚。很少有大规模研究估算 COVID-19 后儿童 MIS-C 和 KD 的累积发病率:方法:数据来自 TriNetX。方法:数据来自 TriNetX,完成倾向得分匹配后,使用 Cox 回归分析了 258,645 例 COVID-19 患者(COVID-19 组)和 258,645 例无 COVID-19 患者(非 COVID-19 组)的数据。计算了两组患者的危险比 (HR)、95% 置信区间 (CI) 以及 MIS-C 和 KD 的累积发病率。为验证结果,还进行了分层分析:在对基线年龄和性别进行匹配后,COVID-19 组的 MIS-C 和 KD 风险高于非 COVID-19 组(HR:分别为 3.023 [95% CI:2.323 至 3.933] 和 1.736 [95% CI:1.273 至 2.369])。在对基线年龄、性别、种族、民族和合并症进行匹配后,COVID-19 组的 MIS-C 和 KD 风险仍显著高于非 COVID-19 组(HR:2.899 [95% CI:2.173 至 3.868] 和 1.435 [95% CI:1.030 至 2.000])。按年龄分层时,COVID-19 组中年龄大于 5 岁和小于 5 岁的患者发生 MIS-C 的风险高于非 COVID-19 组(HR:分别为 2.399 [95% CI:1.683 至 3.418] 和 2.673 [95% CI:1.737 至 4.112])。然而,只有年龄小于 5 岁的患者发生 KD 的风险升高(HR:1.808;95% CI:1.203 至 2.716)。根据COVID-19疫苗接种情况进行分层后,未接种COVID-19疫苗的患者发生MIS-C和KD的风险升高(HR:分别为2.406和1.835):结论:年龄小于18岁和小于5岁的COVID-19患者罹患MIS-C和KD的风险分别增加。结论:年龄小于18岁和小于5岁的COVID-19患者分别会增加MIS-C和KD的风险,需要进一步研究证实COVID-19在MIS-C和KD发病机制中的作用。
{"title":"Risks of Kawasaki disease and multisystem inflammatory syndrome in pediatric patients with COVID-19 infection: A TriNetX based cohort study.","authors":"Kuang-Jen Chien, Cheng-Chung James Wei, Shih-Hui Huang, Chun-Yu Chen, Ho-Chang Kuo, Yao-Min Hung, Pei-Lun Liao, Jing-Yang Huang, Ming-Fang Cheng, Ken-Pen Weng","doi":"10.1097/JCMA.0000000000001137","DOIUrl":"10.1097/JCMA.0000000000001137","url":null,"abstract":"<p><strong>Background: </strong>The associations of coronavirus disease (COVID-19) with Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) remain unclear. Few large-scale studies have estimated the cumulative incidence of MIS-C and KD after COVID-19 in children.</p><p><strong>Methods: </strong>Data were obtained from TriNetX. After propensity score matching was completed, data from 258 645 patients with COVID-19 (COVID-19 group) and 258 645 patients without COVID-19 (non-COVID-19 group) were analyzed using Cox regression. Hazard ratio (HR), 95% CI, and cumulative incidence of MIS-C and KD were calculated for both groups. A stratified analysis was performed to validate the results.</p><p><strong>Results: </strong>After matching for age at baseline and sex, the risks of MIS-C and KD were higher in the COVID-19 group than in the non-COVID-19 group (HR: 3.023 [95% CI, 2.323-3.933] and 1.736 [95% CI, 1.273-2.369], respectively). After matching for age at baseline, sex, race, ethnicity, and comorbidities, the risks of MIS-C and KD remained significantly higher in the COVID-19 group than in the non-COVID-19 group (HR: 2.899 [95% CI, 2.173-3.868] and 1.435 [95% CI, 1.030-2.000]). When stratified by age, the risk of MIS-C was higher in the COVID-19 group-for patients aged >5 years and ≤5 years (HR: 2.399 [95% CI, 1.683-3.418] and 2.673 [95% CI, 1.737-4.112], respectively)-than in the non-COVID-19 group. However, the risk of KD was elevated only in patients aged ≤5 years (HR: 1.808; 95% CI, 1.203-2.716). When stratified by COVID-19 vaccination status, the risks of MIS-C and KD were elevated in unvaccinated patients with COVID-19 (HR: 2.406 and 1.835, respectively).</p><p><strong>Conclusion: </strong>Patients with COVID-19 who are aged <18 and ≤5 years have increased risks of MIS-C and KD, respectively. Further studies are required to confirm the role of COVID-19 in the pathogenesis of MIS-C and KD.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"861-869"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WGCNA reveals a biomarker for cancer-associated fibroblasts to predict prognosis in cervical cancer. WGCNA 揭示了预测宫颈癌预后的癌症相关成纤维细胞生物标志物。
Pub Date : 2024-09-01 Epub Date: 2024-07-01 DOI: 10.1097/JCMA.0000000000001129
Zao-Ling Liu, Nan Chen, Rong Li, Ying-Jie Ma, Aerna Qiayimaerdan, Cai-Ling Ma

Background: Cancer-associated fibroblasts (CAFs) are crucial components of the cervical cancer tumor microenvironment, playing a significant role in cervical cancer progression, treatment resistance, and immune evasion, but whether the expression of CAF-related genes can predict clinical outcomes in cervical cancer is still unknown. In this study, we sought to analyze genes associated with CAFs through weighted gene co-expression network analysis (WGCNA) and to create a predictive model for CAFs in cervical cancer.

Methods: We acquired transcriptome sequencing data and clinical information on cervical cancer patients from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases. WGCNA was conducted to identify genes related to CAFs. We developed a prognostic model based on CAF genes in cervical cancer using the least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Single-cell sequencing data analysis and in vivo experiments for validation of hub genes in CAFs.

Results: A prognostic model for cervical cancer was developed based on CAF genes including COL4A1 , LAMC1 , RAMP3 , POSTN , and SERPINF1 . Cervical cancer patients were divided into low- and high-risk groups based on the optimal cutoff value. Patients in the high-risk group had a significantly worse prognosis. Single-cell RNA sequencing data revealed that hub genes in the CAFs risk model were expressed mainly in fibroblasts. The real-time fluorescence quantitative polymerase chain reaction (PCR) results revealed a significant difference in the expression levels of COL4A1 , LAMC1 , POSTN , and SERPINF1 between the cancer group and the normal group ( p < 0.05). Consistently, the results of the immunohistochemical tests exhibited notable variations in COL4A1, LAMC1, RAMP3, POSTN, and SERPINF1 expression between the cancer and normal groups ( p < 0.001).

Conclusion: The CAF risk model for cervical cancer constructed in this study can be used to predict prognosis, while the CAF hub genes can be utilized as crucial markers for cervical cancer prognosis.

背景:癌症相关成纤维细胞(CAFs)是宫颈癌肿瘤微环境的重要组成部分,在宫颈癌的进展、治疗耐药和免疫逃避中发挥着重要作用,但CAF相关基因的表达能否预测宫颈癌的临床结局仍是未知数。在本研究中,我们试图通过加权基因共表达网络分析(WGCNA)分析与CAFs相关的基因,并建立宫颈癌CAFs的预测模型:我们从 TCGA 和 GEO 数据库中获取了宫颈癌患者的转录组测序数据和临床信息。方法:我们从 TCGA 和 GEO 数据库中获取了宫颈癌患者的转录组测序数据和临床信息,并进行了加权基因共表达网络分析,以确定与 CAFs 相关的基因。我们利用 LASSO Cox 回归分析建立了基于宫颈癌 CAF 基因的预后模型。单细胞测序数据分析和体内实验验证了CAFs中的枢纽基因:结果:基于CAF基因(包括COL4A1、LAMC1、RAMP3、POSTN和SERPINF1)建立了宫颈癌预后模型。根据最佳临界值将宫颈癌患者分为低风险组和高风险组。高风险组患者的预后明显较差。单细胞 RNA 测序数据显示,CAFs 风险模型中的枢纽基因主要在成纤维细胞中表达。实时荧光定量 PCR 结果显示,癌症组与正常组之间 COL4A1、LAMC1、POSTN 和 SERPINF1 的表达水平存在显著差异(P < 0.05)。同样,免疫组化检测结果显示,癌症组与正常组之间 COL4A1、LAMC1、RAMP3、POSTN 和 SERPINF1 的表达也存在显著差异(P < 0.001):结论:本研究构建的宫颈癌CAF风险模型可用于预测预后,而CAF枢纽基因可作为宫颈癌预后的关键标志物。
{"title":"WGCNA reveals a biomarker for cancer-associated fibroblasts to predict prognosis in cervical cancer.","authors":"Zao-Ling Liu, Nan Chen, Rong Li, Ying-Jie Ma, Aerna Qiayimaerdan, Cai-Ling Ma","doi":"10.1097/JCMA.0000000000001129","DOIUrl":"10.1097/JCMA.0000000000001129","url":null,"abstract":"<p><strong>Background: </strong>Cancer-associated fibroblasts (CAFs) are crucial components of the cervical cancer tumor microenvironment, playing a significant role in cervical cancer progression, treatment resistance, and immune evasion, but whether the expression of CAF-related genes can predict clinical outcomes in cervical cancer is still unknown. In this study, we sought to analyze genes associated with CAFs through weighted gene co-expression network analysis (WGCNA) and to create a predictive model for CAFs in cervical cancer.</p><p><strong>Methods: </strong>We acquired transcriptome sequencing data and clinical information on cervical cancer patients from the cancer genome atlas (TCGA) and gene expression omnibus (GEO) databases. WGCNA was conducted to identify genes related to CAFs. We developed a prognostic model based on CAF genes in cervical cancer using the least absolute shrinkage and selection operator (LASSO) Cox regression analysis. Single-cell sequencing data analysis and in vivo experiments for validation of hub genes in CAFs.</p><p><strong>Results: </strong>A prognostic model for cervical cancer was developed based on CAF genes including COL4A1 , LAMC1 , RAMP3 , POSTN , and SERPINF1 . Cervical cancer patients were divided into low- and high-risk groups based on the optimal cutoff value. Patients in the high-risk group had a significantly worse prognosis. Single-cell RNA sequencing data revealed that hub genes in the CAFs risk model were expressed mainly in fibroblasts. The real-time fluorescence quantitative polymerase chain reaction (PCR) results revealed a significant difference in the expression levels of COL4A1 , LAMC1 , POSTN , and SERPINF1 between the cancer group and the normal group ( p < 0.05). Consistently, the results of the immunohistochemical tests exhibited notable variations in COL4A1, LAMC1, RAMP3, POSTN, and SERPINF1 expression between the cancer and normal groups ( p < 0.001).</p><p><strong>Conclusion: </strong>The CAF risk model for cervical cancer constructed in this study can be used to predict prognosis, while the CAF hub genes can be utilized as crucial markers for cervical cancer prognosis.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"885-897"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Risk factors for acute kidney injury or mortality and long-term follow-up in coronavirus disease 2019 infected patients in the era before vaccination. 疫苗接种前 COVID-19 感染者发生 AKI 或死亡的风险因素及长期随访情况。
Pub Date : 2024-09-01 Epub Date: 2024-07-16 DOI: 10.1097/JCMA.0000000000001138
Shu-Ming Chen, Yu-Cheng Hsiao, Chung-Yi Cheng, Che-Yu Lin, Wei-Shian Lai, Guo-Qiang Zeng, Chih-Chin Kao, Mei-Yi Wu, Mai-Szu Wu, Yen-Chung Lin, Raymond K Hsu

Background: Acute kidney injury (AKI) is a severe complication of coronavirus disease 2019 (COVID-19) and is associated with a higher risk of mortality. Understanding the risk factors contributing to COVID-19-related AKI and mortality before vaccination is important for the initiation of preventative measures and early treatment strategies.

Methods: This study included patients aged ≥18 years diagnosed with COVID-19 through polymerase chain reaction from May 2020 to July 2021, admitted in three local hospitals in Taiwan, with an extended follow-up until June 30, 2022. A median follow-up period of 250 days was used to assess AKI development and mortality. AKI was defined according to the Kidney Disease Improving Global Outcomes criteria. Multivarible Cox regression analysis of AKI and mortality-related risk factors were performed.

Results: Of the 720 hospitalized patients with COVID-19, 90 (22%) developed AKI. Moreover, 80%, 10.1%, and 8.9% of the patients had stage 1, 2, and 3 AKI, respectively. Patients with stage 1 to 3 AKI had significantly lower survival rates than those without AKI ( p = 0.001). The mean duration of post-admission AKI occurrence was 9.50 ± 11.32 days. Older age, hypoalbuminemia, and higher D-dimer and ferritin levels were associated with COVID-19 mortality. In COVID-19 AKI, in addition to older age and high D-dimer and ferritin levels, chronic kidney disease emerged as an independent risk factor.

Conclusion: COVID-19-related AKI develops early, exhibits a temporal association with respiratory failure, and is linked to an unfavorable prognosis. The mortality rate increased according to the AKI stage ( p = 0.001). Age, albumin, D-dimer, and ferritin levels, and the underlying chronic kidney disease status upon admission are crucial factors for predicting AKI development, which increases the mortality risk. Monitoring the renal function not only within 10 days of COVID-19 onset, but also within 1 month after the disease onset.

背景:急性肾损伤(AKI)是冠状病毒病2019(COVID-19)的一种严重并发症,与较高的死亡风险相关。在接种疫苗前了解导致COVID-19相关急性肾损伤和死亡的风险因素对于启动预防措施和早期治疗策略非常重要:本研究纳入了 2020 年 5 月至 2021 年 7 月期间在台湾三家当地医院通过聚合酶链反应确诊为 COVID-19 的≥18 岁患者,并延长随访至 2022 年 6 月 30 日。中位随访期为 250 天,用于评估 AKI 的发展和死亡率。AKI根据肾脏疾病改善全球结果标准进行定义。对AKI和死亡率相关风险因素进行了多变量Cox回归分析:在720名COVID-19住院患者中,有90人(22%)发生了AKI。此外,分别有80%、10.1%和8.9%的患者出现了1期、2期和3期AKI。1-3 期 AKI 患者的存活率明显低于无 AKI 患者(P = 0.0012)。入院后发生 AKI 的平均持续时间为 9.50 ± 11.32 天。高龄、低白蛋白血症、较高的 D-二聚体和铁蛋白水平与 COVID-19 死亡率相关。在 COVID-19 AKI 中,除了高龄、高 D-二聚体和铁蛋白水平外,慢性肾病也是一个独立的风险因素:结论:COVID-19 相关性 AKI 发病早,与呼吸衰竭有时间上的关联,预后不良。死亡率随 AKI 分期的增加而增加(p = 0.0012)。年龄、白蛋白、D-二聚体和铁蛋白水平以及入院时的慢性肾脏疾病状况是预测 AKI 发展的关键因素,而 AKI 会增加死亡风险。不仅要在 COVID-19 发病 10 天内监测肾功能,还要在发病后一个月内监测肾功能。
{"title":"Risk factors for acute kidney injury or mortality and long-term follow-up in coronavirus disease 2019 infected patients in the era before vaccination.","authors":"Shu-Ming Chen, Yu-Cheng Hsiao, Chung-Yi Cheng, Che-Yu Lin, Wei-Shian Lai, Guo-Qiang Zeng, Chih-Chin Kao, Mei-Yi Wu, Mai-Szu Wu, Yen-Chung Lin, Raymond K Hsu","doi":"10.1097/JCMA.0000000000001138","DOIUrl":"10.1097/JCMA.0000000000001138","url":null,"abstract":"<p><strong>Background: </strong>Acute kidney injury (AKI) is a severe complication of coronavirus disease 2019 (COVID-19) and is associated with a higher risk of mortality. Understanding the risk factors contributing to COVID-19-related AKI and mortality before vaccination is important for the initiation of preventative measures and early treatment strategies.</p><p><strong>Methods: </strong>This study included patients aged ≥18 years diagnosed with COVID-19 through polymerase chain reaction from May 2020 to July 2021, admitted in three local hospitals in Taiwan, with an extended follow-up until June 30, 2022. A median follow-up period of 250 days was used to assess AKI development and mortality. AKI was defined according to the Kidney Disease Improving Global Outcomes criteria. Multivarible Cox regression analysis of AKI and mortality-related risk factors were performed.</p><p><strong>Results: </strong>Of the 720 hospitalized patients with COVID-19, 90 (22%) developed AKI. Moreover, 80%, 10.1%, and 8.9% of the patients had stage 1, 2, and 3 AKI, respectively. Patients with stage 1 to 3 AKI had significantly lower survival rates than those without AKI ( p = 0.001). The mean duration of post-admission AKI occurrence was 9.50 ± 11.32 days. Older age, hypoalbuminemia, and higher D-dimer and ferritin levels were associated with COVID-19 mortality. In COVID-19 AKI, in addition to older age and high D-dimer and ferritin levels, chronic kidney disease emerged as an independent risk factor.</p><p><strong>Conclusion: </strong>COVID-19-related AKI develops early, exhibits a temporal association with respiratory failure, and is linked to an unfavorable prognosis. The mortality rate increased according to the AKI stage ( p = 0.001). Age, albumin, D-dimer, and ferritin levels, and the underlying chronic kidney disease status upon admission are crucial factors for predicting AKI development, which increases the mortality risk. Monitoring the renal function not only within 10 days of COVID-19 onset, but also within 1 month after the disease onset.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"828-835"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Course-based intra-articular injection of medical chitosan mitigates excessive deposition of triacylglycerides in the synovial tissue of the knee osteoarthritis. 在关节内注射医用壳聚糖可减轻膝关节骨关节炎滑膜组织中三酰甘油的过度沉积。
Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1097/JCMA.0000000000001133
Qi-Hang Su, Li-Yang Chen, Qiu-Chen Cai, Heng-An Ge, Jun Li, Cen-Tao Liu, Chao Xue, Jing-Biao Huang, Cheng-Long Huang, Xiao-Fei Feng, Biao Cheng

Background: This study aimed to investigate the clinical efficacy of intra-articular injections of medical chitosan for treating knee osteoarthritis (KOA) and measure the lipid metabolism profiles of the synovial tissue.

Methods: Sixty patients with KOA undergoing conservative treatment were recruited and randomized into two groups: one without pharmacological intervention (OA group) and the other receiving course-based intra-articular medical chitosan injections (CSI group). Quantitative lipidomic profile of synovial tissue was analyzed. Functional scores, including Kellgren-Lawrence rating (K-L), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scoring, and American Knee Society (AKS) scoring were conducted.

Results: Survival from the initial conservative treatment to final knee arthroplasty was significantly longer in the CSI group compared to the OA group. Except for the presurgery VAS score, no statistically significant differences were observed in the other scores, including K-L, initial VAS, WOMAC, and AKS. However, the CSI group experienced more reductions in AKS-Knee subscores compared to the OA group. Compared to the CSI group, the OA group exhibited a significant upregulation in most differential lipids, particularly triacylglycerides (TAGs, 77%). The OA group had notably higher levels of long-chain unsaturated fatty acids.

Conclusion: Intra-articular injection of medical chitosan significantly prolongs the survival period before knee arthroplasty and reduces the deposition of TAGs metabolites.

研究背景方法:招募60名接受保守治疗的KOA患者,将其随机分为两组:一组不进行药物干预(OA组),另一组接受疗程性关节内注射壳聚糖(CSI组)。对滑膜组织的脂质组学定量分析。进行了功能评分,包括凯尔格伦-劳伦斯评分(K-L)、VAS、WOMAC评分和AKS评分:结果:与 OA 组相比,CSI 组从最初的保守治疗到最终的膝关节置换术的存活时间明显更长。除手术前的 VAS 评分外,其他评分(包括 K-L、初始 VAS、WOMAC 和 AKS)均无统计学差异。不过,与 OA 组相比,CSI 组的 AKS-膝关节子分数下降略微明显。与 CSI 组相比,OA 组的大多数不同脂质,尤其是三酰甘油(TAGs,77%),都出现了明显的上调。OA 组的长链不饱和脂肪酸水平明显更高:结论:关节内注射医用壳聚糖可明显延长膝关节置换术前的存活期,并减少 TAGs 代谢物的沉积。
{"title":"Course-based intra-articular injection of medical chitosan mitigates excessive deposition of triacylglycerides in the synovial tissue of the knee osteoarthritis.","authors":"Qi-Hang Su, Li-Yang Chen, Qiu-Chen Cai, Heng-An Ge, Jun Li, Cen-Tao Liu, Chao Xue, Jing-Biao Huang, Cheng-Long Huang, Xiao-Fei Feng, Biao Cheng","doi":"10.1097/JCMA.0000000000001133","DOIUrl":"10.1097/JCMA.0000000000001133","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the clinical efficacy of intra-articular injections of medical chitosan for treating knee osteoarthritis (KOA) and measure the lipid metabolism profiles of the synovial tissue.</p><p><strong>Methods: </strong>Sixty patients with KOA undergoing conservative treatment were recruited and randomized into two groups: one without pharmacological intervention (OA group) and the other receiving course-based intra-articular medical chitosan injections (CSI group). Quantitative lipidomic profile of synovial tissue was analyzed. Functional scores, including Kellgren-Lawrence rating (K-L), Visual Analog Scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scoring, and American Knee Society (AKS) scoring were conducted.</p><p><strong>Results: </strong>Survival from the initial conservative treatment to final knee arthroplasty was significantly longer in the CSI group compared to the OA group. Except for the presurgery VAS score, no statistically significant differences were observed in the other scores, including K-L, initial VAS, WOMAC, and AKS. However, the CSI group experienced more reductions in AKS-Knee subscores compared to the OA group. Compared to the CSI group, the OA group exhibited a significant upregulation in most differential lipids, particularly triacylglycerides (TAGs, 77%). The OA group had notably higher levels of long-chain unsaturated fatty acids.</p><p><strong>Conclusion: </strong>Intra-articular injection of medical chitosan significantly prolongs the survival period before knee arthroplasty and reduces the deposition of TAGs metabolites.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"870-877"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bibliographic analysis of psychiatric publications in Taiwan: An analysis of Web of Science subject category from 1970 to 2023. 台湾精神病学出版物的书目分析:1970-2023年Web of Science主题分类分析。
Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1097/JCMA.0000000000001135
Isabel Mei-Hsuan Huang, Faug-Ju Tsai, Yu-Chun Chen, Shih-Jen Tsai, Shinn-Jang Hwang

Background: Mental diseases continue to rank among the top 10 leading causes of global burden. Psychiatric research is a crucial avenue through which mental healthcare can be enhanced. Taiwanese academics have constantly concentrated their efforts on psychiatric research and published their findings. A systematic examination of these papers will provide an assessment of the present state and contribute to the formulation of future policies for psychiatric research in Taiwan. We assessed psychiatric papers from Taiwan using the Web of Science (WoS) database.

Methods: Academic papers in the Psychiatry category of the WoS database from Taiwan were retrieved and evaluated. The analysis included papers published in Science Citation Index-Expanded and Social Science Citation Indexed journals between 1970 and 2023, excluding meeting abstracts and corrections.

Results: Of the 1 049 281 papers published globally in the Psychiatry category of the WoS system between 1970 and 2023, 6117 (0.58%) were published in Taiwan. Taiwan ranked 26th globally in terms of number of papers published. These publications have received 150 519 citations. Over the past 53 years, both the annual number of psychiatric papers from Taiwan and their citations received have significantly and rapidly increased. However, the average impact factor of publications remained constant over time.

Conclusion: Over the last five decades, the number of psychiatric publications from Taiwan has increased. However, the average impact factor of these published papers did not increase over time. Investing in advanced research infrastructure and interdisciplinary projects may improve the quality and relevance of Taiwanese psychiatric research publications, potentially increasing their global citations and impact.

背景:精神疾病仍然是造成全球负担的十大主要原因之一。精神病学研究是加强精神保健的重要途径。台湾学者一直致力于精神病学研究,并发表了大量研究成果。通过对这些论文进行系统性的研究,可以对台湾精神科研究的现状进行评估,并有助于未来政策的制定。我们使用 Web of Science(WoS)数据库对台湾的精神病学论文进行了评估:方法:检索并评估了台湾 WoS 数据库精神病学类别中的学术论文。分析包括1970年至2023年间发表在《科学引文索引-扩展版》和《社会科学引文索引》期刊上的论文,不包括会议摘要和更正:结果:1970 年至 2023 年间,全球共发表 1,049,281 篇 WoS 系统精神病学类论文,其中 6,117 篇(0.58%)发表于台湾。台湾发表的论文数量在全球排名第二十六位。这些论文共被引用 150,519 次。在过去的 53 年中,台湾每年发表的精神病学论文数量和论文被引用次数都在显著快速增长。然而,论文的平均影响因子却始终保持不变:结论:在过去的五十年中,台湾发表的精神医学论文数量有所增加。结论:在过去的五十年中,台湾发表的精神病学论文数量有所增加,但这些论文的平均影响因子并未随时间推移而增加。投资于先进的研究基础设施和跨学科项目可能会提高台湾精神病学研究出版物的质量和相关性,从而有可能增加其全球引用率和影响力。
{"title":"Bibliographic analysis of psychiatric publications in Taiwan: An analysis of Web of Science subject category from 1970 to 2023.","authors":"Isabel Mei-Hsuan Huang, Faug-Ju Tsai, Yu-Chun Chen, Shih-Jen Tsai, Shinn-Jang Hwang","doi":"10.1097/JCMA.0000000000001135","DOIUrl":"10.1097/JCMA.0000000000001135","url":null,"abstract":"<p><strong>Background: </strong>Mental diseases continue to rank among the top 10 leading causes of global burden. Psychiatric research is a crucial avenue through which mental healthcare can be enhanced. Taiwanese academics have constantly concentrated their efforts on psychiatric research and published their findings. A systematic examination of these papers will provide an assessment of the present state and contribute to the formulation of future policies for psychiatric research in Taiwan. We assessed psychiatric papers from Taiwan using the Web of Science (WoS) database.</p><p><strong>Methods: </strong>Academic papers in the Psychiatry category of the WoS database from Taiwan were retrieved and evaluated. The analysis included papers published in Science Citation Index-Expanded and Social Science Citation Indexed journals between 1970 and 2023, excluding meeting abstracts and corrections.</p><p><strong>Results: </strong>Of the 1 049 281 papers published globally in the Psychiatry category of the WoS system between 1970 and 2023, 6117 (0.58%) were published in Taiwan. Taiwan ranked 26th globally in terms of number of papers published. These publications have received 150 519 citations. Over the past 53 years, both the annual number of psychiatric papers from Taiwan and their citations received have significantly and rapidly increased. However, the average impact factor of publications remained constant over time.</p><p><strong>Conclusion: </strong>Over the last five decades, the number of psychiatric publications from Taiwan has increased. However, the average impact factor of these published papers did not increase over time. Investing in advanced research infrastructure and interdisciplinary projects may improve the quality and relevance of Taiwanese psychiatric research publications, potentially increasing their global citations and impact.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"836-841"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Percutaneous transluminal angioplasty and stenting for severe stenosis of the intracranial carotid artery and its branches: Comparison of the Wingspan stent vs the Credo stent. 经皮腔内血管成形术和支架植入术治疗颅内颈动脉及其分支严重狭窄:Wingspan 支架与 Credo 支架的比较。
Pub Date : 2024-09-01 Epub Date: 2024-07-08 DOI: 10.1097/JCMA.0000000000001131
Te-Ming Lin, Chia-Hung Wu, Chih-Ping Chung, Kai-Wei Yu, Wei-An Tai, Chao-Bao Luo, Jiing-Feng Lirng, Feng-Chi Chang

Background: Despite the widespread use of the Wingspan stent system for treating severe medically refractory intracranial artery stenosis (SMR-ICAS), a new Credo stent system was approved because it could integrate stent delivery within the balloon catheter. However, the therapeutic outcomes of these two systems have not been compared. This preliminary study aimed to compare the results of percutaneous angioplasty and stenting (PTAS) in SMR-ICAS patients treated with either Wingspan or Credo stents within the anterior cerebral circulation.

Methods: SMR-ICAS patients with >70% stenosis in the anterior circulation who underwent PTAS using either the Wingspan or Credo stent system were retrospectively analyzed. We evaluated the technical success, safety, and outcomes of the two-stent systems.

Results: A total of 29 patients were analyzed, including 17 patients treated with Wingspan stents and 12 with Credo stents. The outcomes of the Wingspan stent vs Credo stent were as follows: technical success (16/17 [94%] vs 11/12 [92%], p = 1.00); periprocedural intracranial hemorrhage (2/17 [12%] vs 0/12 [0%], p = 0.50); silent embolic ischemic lesions on periprocedural magnetic resonance imaging (MRI) (13/17 [76%] vs 7/12 [58%], p = 0.42); and significant (>50%) in-stent restenosis in 1 year (4/17 [24%] vs 2/12 [17%], p = 1.00). No recurrent stroke or mortality was noted within 30 days after the procedures or during the 1-year follow-up period.

Conclusion: The technical success, safety, and outcomes of the Credo stent system were comparable to those of the Wingspan stent system in the management of SMR-ICAS patients. Further large-scale studies are warranted to substantiate these findings.

背景:尽管 Wingspan 支架系统已被广泛用于治疗严重的药物难治性颅内动脉狭窄(SMR-ICAS),但新的 Credo 支架系统因能在球囊导管内整合支架输送而获得批准。然而,这两种系统的治疗效果尚未进行比较。这项初步研究旨在比较在前循环中使用 Wingspan 或 Credo 支架治疗 SMR-ICAS 患者的经皮血管成形术和支架植入术(PTAS)的效果:分析了使用 Wingspan 或 Credo 支架系统进行经皮血管成形术和支架植入术(PTAS)的前循环狭窄超过 70% 的 SMR-ICAS 患者。我们评估了两种支架系统的技术成功率、安全性和疗效:结果:共分析了29例患者,其中17例使用Wingspan支架,12例使用Credo支架。Wingspan支架与Credo支架的疗效对比如下:技术成功率(16/17 [94%] vs. 11/12 [92%],P = 1.00);围手术期颅内出血(2/17 [12%] vs. 0/12 [0%],P = 0.50);围手术期磁共振成像显示无声栓塞性缺血性病变(13/17 [76%] vs. 7/12 [58%],p = 0.42);一年内支架内再狭窄显著(超过 50%)(4/17 [24%] vs. 2/12 [17%],p = 1.00)。术后 30 天内或一年随访期间未发现复发中风或死亡:结论:在治疗 SMR-ICAS 患者方面,Credo 支架系统的技术成功率、安全性和疗效与 Wingspan 支架系统相当。有必要进一步开展大规模研究,以证实这些研究结果。
{"title":"Percutaneous transluminal angioplasty and stenting for severe stenosis of the intracranial carotid artery and its branches: Comparison of the Wingspan stent vs the Credo stent.","authors":"Te-Ming Lin, Chia-Hung Wu, Chih-Ping Chung, Kai-Wei Yu, Wei-An Tai, Chao-Bao Luo, Jiing-Feng Lirng, Feng-Chi Chang","doi":"10.1097/JCMA.0000000000001131","DOIUrl":"10.1097/JCMA.0000000000001131","url":null,"abstract":"<p><strong>Background: </strong>Despite the widespread use of the Wingspan stent system for treating severe medically refractory intracranial artery stenosis (SMR-ICAS), a new Credo stent system was approved because it could integrate stent delivery within the balloon catheter. However, the therapeutic outcomes of these two systems have not been compared. This preliminary study aimed to compare the results of percutaneous angioplasty and stenting (PTAS) in SMR-ICAS patients treated with either Wingspan or Credo stents within the anterior cerebral circulation.</p><p><strong>Methods: </strong>SMR-ICAS patients with >70% stenosis in the anterior circulation who underwent PTAS using either the Wingspan or Credo stent system were retrospectively analyzed. We evaluated the technical success, safety, and outcomes of the two-stent systems.</p><p><strong>Results: </strong>A total of 29 patients were analyzed, including 17 patients treated with Wingspan stents and 12 with Credo stents. The outcomes of the Wingspan stent vs Credo stent were as follows: technical success (16/17 [94%] vs 11/12 [92%], p = 1.00); periprocedural intracranial hemorrhage (2/17 [12%] vs 0/12 [0%], p = 0.50); silent embolic ischemic lesions on periprocedural magnetic resonance imaging (MRI) (13/17 [76%] vs 7/12 [58%], p = 0.42); and significant (>50%) in-stent restenosis in 1 year (4/17 [24%] vs 2/12 [17%], p = 1.00). No recurrent stroke or mortality was noted within 30 days after the procedures or during the 1-year follow-up period.</p><p><strong>Conclusion: </strong>The technical success, safety, and outcomes of the Credo stent system were comparable to those of the Wingspan stent system in the management of SMR-ICAS patients. Further large-scale studies are warranted to substantiate these findings.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"878-884"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Therapeutic efficacy of platelet-rich plasma in the management of rib fractures. 富血小板血浆在治疗肋骨骨折中的疗效。
Pub Date : 2024-09-01 Epub Date: 2024-07-15 DOI: 10.1097/JCMA.0000000000001136
Yi-Han Lin, Han-Shui Hsu

Background: This study aimed to investigate the therapeutic efficacy of platelet-rich plasma (PRP) therapy in patients with rib fractures.

Methods: This study retrospectively collected data from patients with acute rib fractures at Ming-Sheng General Hospital from 2020 to 2022 and excluded those who underwent surgical intervention or with severe extrathoracic injuries. PRP was extracted using the patient's blood and injected via ultrasound guidance near the fracture site. Patients self-assessed pain levels and medication usage at 0, 1, 2, 4, and 8 weeks. Pulmonary function tests were conducted at 4 weeks.

Results: This study included 255 patients, with 160 and 95 patients in the conservative (only pain medications administered) and PRP groups (PRP and analgesics administered), respectively. The PRP group reported lower pain levels than the conservative group at 2 and 4 weeks. No substantial differences in medication usage were observed between the groups. The PRP group demonstrated lower pain levels and medication usage than the conservative group in severe rib fractures (≥3 ribs) and better lung function improvement at 4 weeks. After propensity score matching, the PRP group still had a better treatment outcome in pain control and lung function recovery.

Conclusion: PRP demonstrated considerable therapeutic efficacy in patients with severe rib fractures, resulting in reduced pain, decreased medication usage, and improved lung function but with no substantial benefits in patients with mild rib fractures.

背景:本研究旨在探讨富血小板血浆(PRP)疗法对肋骨骨折患者的疗效:本研究旨在探讨富血小板血浆(PRP)治疗肋骨骨折患者的疗效:本研究回顾性收集了明升综合医院 2020 年至 2022 年急性肋骨骨折患者的数据,排除了接受手术治疗或严重胸外损伤的患者。研究使用患者的血液提取 PRP,并通过超声引导在骨折部位附近注射。患者在 0、1、2、4 和 8 周时对疼痛程度和用药情况进行自我评估。4周时进行肺功能测试:这项研究包括 255 名患者,其中保守组(仅使用止痛药)和 PRP 组(使用 PRP 和止痛药)分别有 160 名和 95 名患者。在 2 周和 4 周时,PRP 组的疼痛程度低于保守治疗组。两组在用药方面没有明显差异。在严重肋骨骨折(≥3 根肋骨)患者中,PRP 组的疼痛程度和用药量大大低于保守治疗组,并且在 4 周时肺功能有所改善。经过倾向评分匹配后,PRP 组在疼痛控制和肺功能恢复方面仍有更好的治疗效果:结论:PRP 对严重肋骨骨折患者具有显著疗效,可减轻疼痛、减少用药量并改善肺功能,但对轻度肋骨骨折患者无实质性益处。
{"title":"Therapeutic efficacy of platelet-rich plasma in the management of rib fractures.","authors":"Yi-Han Lin, Han-Shui Hsu","doi":"10.1097/JCMA.0000000000001136","DOIUrl":"10.1097/JCMA.0000000000001136","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the therapeutic efficacy of platelet-rich plasma (PRP) therapy in patients with rib fractures.</p><p><strong>Methods: </strong>This study retrospectively collected data from patients with acute rib fractures at Ming-Sheng General Hospital from 2020 to 2022 and excluded those who underwent surgical intervention or with severe extrathoracic injuries. PRP was extracted using the patient's blood and injected via ultrasound guidance near the fracture site. Patients self-assessed pain levels and medication usage at 0, 1, 2, 4, and 8 weeks. Pulmonary function tests were conducted at 4 weeks.</p><p><strong>Results: </strong>This study included 255 patients, with 160 and 95 patients in the conservative (only pain medications administered) and PRP groups (PRP and analgesics administered), respectively. The PRP group reported lower pain levels than the conservative group at 2 and 4 weeks. No substantial differences in medication usage were observed between the groups. The PRP group demonstrated lower pain levels and medication usage than the conservative group in severe rib fractures (≥3 ribs) and better lung function improvement at 4 weeks. After propensity score matching, the PRP group still had a better treatment outcome in pain control and lung function recovery.</p><p><strong>Conclusion: </strong>PRP demonstrated considerable therapeutic efficacy in patients with severe rib fractures, resulting in reduced pain, decreased medication usage, and improved lung function but with no substantial benefits in patients with mild rib fractures.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"854-860"},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141629631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Biomechanical evaluation of 3D-printed joint-type orthosis for hallux valgus. 三维打印关节型外翻矫形器的生物力学评估。
Pub Date : 2024-08-01 Epub Date: 2024-06-18 DOI: 10.1097/JCMA.0000000000001120
Chen-Sheng Chen, Yu-Sheng Chang, Kuang-Wei Lin, Mu-Jung Chien, Chien-Shun Wang

Background: Orthoses play an important role in the conservative treatment of hallux valgus (HV) with different therapeutic effects. In this study, a new HV orthosis was developed using three-dimensional (3D) printing technology. In addition, its kinematic effect was evaluated using motion analysis.

Methods: Seventeen participants with an HV angle of >20° were included in the study. The first metatarsophalangeal abduction angle before and after the orthosis was measured statically. Subsequently, dynamic first metatarsophalangeal abduction, dorsiflexion angle and ground reaction force with and without the orthosis were recorded and calculated during walking using a Vicon motion analysis system and force plates. The patients' comfort scales were determined after the motion analysis.

Results: The angular corrections of the orthosis in the first metatarsophalangeal abduction were 14.6° and 6.3° under static and dynamic conditions, respectively. Reduced hallux dorsiflexion was observed with the orthosis in the early stance phase. However, no significant changes in ground reaction forces were observed.

Conclusion: The results of our study confirm the potential of the 3D-printed HV orthosis in the static and dynamic correction of deformities while ensuring patient comfort with minimal impact on hallux kinematics, suggesting the potential of our design for long-term use.

背景:矫形器在足外翻(HV)的保守治疗中发挥着重要作用,具有不同的治疗效果。本研究利用三维(3D)打印技术开发了一种新的HV矫形器。此外,还通过运动分析对其运动效果进行了评估:研究纳入了 17 名 HV 角度大于 20° 的参与者。对矫形器使用前后的第一跖趾外展角度进行了静态测量。随后,使用 Vicon 运动分析系统和测力板记录并计算了佩戴矫形器和未佩戴矫形器时的动态第一跖趾外展、背屈角度和地面反作用力。运动分析后确定了患者的舒适度评分:结果:在静态和动态条件下,矫形器对第一跖趾外展的角度修正分别为 14.6° 和 6.3°。在早期站立阶段,可以观察到矫形器减少了拇指外翻。然而,地面反作用力没有发生明显变化:我们的研究结果证实了三维打印 HV 矫正器在静态和动态矫正畸形方面的潜力,同时确保了患者的舒适度,并将对拇指外翻运动学的影响降至最低,这表明我们的设计具有长期使用的潜力。
{"title":"Biomechanical evaluation of 3D-printed joint-type orthosis for hallux valgus.","authors":"Chen-Sheng Chen, Yu-Sheng Chang, Kuang-Wei Lin, Mu-Jung Chien, Chien-Shun Wang","doi":"10.1097/JCMA.0000000000001120","DOIUrl":"10.1097/JCMA.0000000000001120","url":null,"abstract":"<p><strong>Background: </strong>Orthoses play an important role in the conservative treatment of hallux valgus (HV) with different therapeutic effects. In this study, a new HV orthosis was developed using three-dimensional (3D) printing technology. In addition, its kinematic effect was evaluated using motion analysis.</p><p><strong>Methods: </strong>Seventeen participants with an HV angle of >20° were included in the study. The first metatarsophalangeal abduction angle before and after the orthosis was measured statically. Subsequently, dynamic first metatarsophalangeal abduction, dorsiflexion angle and ground reaction force with and without the orthosis were recorded and calculated during walking using a Vicon motion analysis system and force plates. The patients' comfort scales were determined after the motion analysis.</p><p><strong>Results: </strong>The angular corrections of the orthosis in the first metatarsophalangeal abduction were 14.6° and 6.3° under static and dynamic conditions, respectively. Reduced hallux dorsiflexion was observed with the orthosis in the early stance phase. However, no significant changes in ground reaction forces were observed.</p><p><strong>Conclusion: </strong>The results of our study confirm the potential of the 3D-printed HV orthosis in the static and dynamic correction of deformities while ensuring patient comfort with minimal impact on hallux kinematics, suggesting the potential of our design for long-term use.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"809-814"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141422325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Short-term outcomes of short- and long-course chemoradiotherapy before total mesorectal excision for locally advanced rectal tumors: A single-center study in Taiwan utilizing propensity score matching. 局部晚期直肠肿瘤全直肠系膜切除术前短期和长期化放疗的短期疗效:利用倾向得分匹配法在台湾开展的一项单中心研究。
Pub Date : 2024-08-01 Epub Date: 2024-06-25 DOI: 10.1097/JCMA.0000000000001127
Chih-Hsien Chang, Shih-Ching Chang, Jeng-Kai Jiang, Huann-Sheng Wang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yi-Wen Yang, Yu-Zu Lin

Background: Locally advanced rectal tumors are typically treated with neoadjuvant chemoradiotherapy. Short-course chemoradiotherapy (SCRT, 2500 cGy in five fractions) is a convenient alternative to concurrent chemoradiotherapy with long-course radiotherapy (CCRT, 4500 cGy in 25 fractions) without sacrificing efficacy. We aimed to compare the short-term outcomes of SCRT and CCRT in patients with mid- and low- rectal tumors who underwent total mesorectal excision using real-world data.

Methods: We retrospectively reviewed the data of patients with locally advanced rectal cancer who underwent radical resection after neoadjuvant chemoradiotherapy from 2011 to 2022. We analyzed the clinicopathological findings and prognostic factors for disease-free and overall survival in the SCRT and CCRT groups and compared the outcomes using propensity score matching.

Results: Among the 66 patients in the two groups, no disparities were noted in the demographic features, pathological remission, or downstaging rates. Nonetheless, the SCRT group exhibited superior 3-year disease-free survival (81.8% vs 62.1%, p = 0.011), whereas the overall survival did not differ significantly between the two groups. The initial carcinoembryonic antigen (CEA) levels and neoadjuvant SCRT were associated with the recurrence rates [hazard ratio (HR) = 1.13-4.10; HR = 0.19-0.74], but the harvested lymph node count was not (HR = 0.51-1.97).

Conclusion: Among patients with locally advanced rectal cancer, SCRT combined with four cycles of FOLFOX was shown to enhance short-term disease-free survival. Factors impacting recurrence include the initial CEA level and SCRT, but not the harvested lymph node count.

背景:局部晚期直肠肿瘤通常采用新辅助化放疗。短程化放疗(SCRT,2,500 cGy,5次分次放疗)是长程放疗(CCRT,4,500 cGy,25次分次放疗)同时进行化放疗的便捷替代方案,且不会降低疗效。我们的目的是利用真实世界的数据,比较接受全直肠系膜切除术的中低位直肠肿瘤患者接受 SCRT 和 CCRT 的短期疗效:我们回顾性分析了2011年至2022年间接受新辅助化放疗后进行根治性切除的局部晚期直肠癌患者的数据。我们分析了SCRT组和CCRT组的临床病理结果以及无病生存期和总生存期的预后因素,并采用倾向评分匹配法对结果进行了比较:在两组的66名患者中,人口统计学特征、病理缓解率和降期率均无差异。然而,SCRT 组的 3 年无病生存率更高(81.8% 对 62.1%,P = 0.011),而两组的总生存率没有显著差异。最初的癌胚抗原(CEA)水平和新辅助SCRT与复发率相关[危险比(HR)1.13-4.10;HR 0.19-0.74],但收获的淋巴结数量与复发率无关(HR 0.51-1.97):结论:在局部晚期直肠癌患者中,SCRT联合四个周期的FOLFOX可提高短期无病生存率。影响复发的因素包括初始CEA水平和SCRT,但不包括收获的淋巴结数量。
{"title":"Short-term outcomes of short- and long-course chemoradiotherapy before total mesorectal excision for locally advanced rectal tumors: A single-center study in Taiwan utilizing propensity score matching.","authors":"Chih-Hsien Chang, Shih-Ching Chang, Jeng-Kai Jiang, Huann-Sheng Wang, Yuan-Tzu Lan, Chun-Chi Lin, Hung-Hsin Lin, Sheng-Chieh Huang, Hou-Hsuan Cheng, Yi-Wen Yang, Yu-Zu Lin","doi":"10.1097/JCMA.0000000000001127","DOIUrl":"10.1097/JCMA.0000000000001127","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced rectal tumors are typically treated with neoadjuvant chemoradiotherapy. Short-course chemoradiotherapy (SCRT, 2500 cGy in five fractions) is a convenient alternative to concurrent chemoradiotherapy with long-course radiotherapy (CCRT, 4500 cGy in 25 fractions) without sacrificing efficacy. We aimed to compare the short-term outcomes of SCRT and CCRT in patients with mid- and low- rectal tumors who underwent total mesorectal excision using real-world data.</p><p><strong>Methods: </strong>We retrospectively reviewed the data of patients with locally advanced rectal cancer who underwent radical resection after neoadjuvant chemoradiotherapy from 2011 to 2022. We analyzed the clinicopathological findings and prognostic factors for disease-free and overall survival in the SCRT and CCRT groups and compared the outcomes using propensity score matching.</p><p><strong>Results: </strong>Among the 66 patients in the two groups, no disparities were noted in the demographic features, pathological remission, or downstaging rates. Nonetheless, the SCRT group exhibited superior 3-year disease-free survival (81.8% vs 62.1%, p = 0.011), whereas the overall survival did not differ significantly between the two groups. The initial carcinoembryonic antigen (CEA) levels and neoadjuvant SCRT were associated with the recurrence rates [hazard ratio (HR) = 1.13-4.10; HR = 0.19-0.74], but the harvested lymph node count was not (HR = 0.51-1.97).</p><p><strong>Conclusion: </strong>Among patients with locally advanced rectal cancer, SCRT combined with four cycles of FOLFOX was shown to enhance short-term disease-free survival. Factors impacting recurrence include the initial CEA level and SCRT, but not the harvested lymph node count.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"774-781"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hirsutella sinensis intensifies testicular function and spermatogenesis in male mice with high-fat diet-induced obesity. 中药赫氏菌能增强高脂饮食导致肥胖的雄性小鼠的睾丸功能和精子发生。
Pub Date : 2024-08-01 Epub Date: 2024-07-01 DOI: 10.1097/JCMA.0000000000001128
Chin-Yu Liu, Chin-Chu Chen, Lynn-Huey Chiang, Bi-Hua Yang, Ting-Chia Chang, Chih-Wei Tsao

Background: Hirsutella sinensis (HS) is a mycelium isolated from the fruiting body of the medicinal mushroom Cordyceps sinensis . This study explored whether HS treatment affects reproductive dysfunction in a high-fat diet (HFD)-induced mouse model and regulates various mechanisms, focusing on oxidative stress, apoptosis, inflammation, and autophagy.

Methods: Twenty-four C57BL/6J (B6) mice were randomly divided into a standard chow diet (NCD)- or HFD-fed group for 24 weeks. During the final 8 weeks, half of the HFD-fed mice were orally administered HS (HFD + HS). Biochemical markers, including glucose, insulin, triglycerides, and total cholesterol, were assessed, and hormones, including testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), were analyzed. Liver and testicular histology, as well as sperm quality markers such as sperm motility, sperm count, and percentage of sperm with normal morphology, were observed. The activities of the testicular antioxidants superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) and the products of lipid peroxidation, such as malondialdehyde (MDA), were measured. The protein expression levels of apoptosis-, autophagy- and inflammation-related markers were measured.

Results: The HFD-fed mice had abnormal sex hormone levels, poor sperm quality, and a destroyed testicular structure, with increased oxidative stress and apoptosis in the testis. HS supplementation in HFD-fed mice attenuated testicular apoptosis by suppressing the Bax/Bcl-xl ratio and cleaved caspase 3 protein expression. The HS-treated mice exhibited improved reproductive function, possibly due to reduced oxidative stress and apoptosis, suggesting that HS has a protective effect against HFD-induced testicular damage.

Conclusion: Male mice supplemented with HS exhibited attenuated poor semen quality and reduced testosterone levels brought about by HFD-induced obesity by reducing oxidative stress.

背景:Hirsutella sinensis(HS)是从药用蘑菇冬虫夏草子实体中分离出来的菌丝体。本研究探讨了HS治疗是否会影响高脂饮食(HFD)诱导的小鼠模型的生殖功能障碍并调节各种机制,重点关注氧化应激、细胞凋亡、炎症和自噬:24只C57BL/6J(B6)小鼠被随机分为标准饲料(NCD)组或HFD组,饲养24周。在最后8周,一半的HFD喂养小鼠口服HS(HFD+HS)。评估生化指标,包括葡萄糖、胰岛素、甘油三酯和总胆固醇,并分析激素,包括睾酮、卵泡刺激素(FSH)和黄体生成素(LH)。还观察了肝脏和睾丸组织学以及精子质量指标,如精子活力、精子数量和形态正常精子的百分比。测量了睾丸抗氧化剂超氧化物歧化酶(SOD)、过氧化氢酶和谷胱甘肽过氧化物酶(GPx)的活性以及脂质过氧化产物(如 MDA)。还测定了与细胞凋亡、自噬和炎症相关的标志物的蛋白表达水平:结果:HFD喂养的小鼠性激素水平异常,精子质量差,睾丸结构遭到破坏,睾丸中的氧化应激和细胞凋亡增加。在高密度脂蛋白饲料喂养的小鼠体内补充 HS 可抑制 Bax/Bcl-xl 比率和裂解的 caspase 3 蛋白表达,从而减轻睾丸凋亡。经 HS 处理的小鼠生殖功能得到改善,这可能是由于氧化应激和细胞凋亡减少所致,表明 HS 对 HFD 引起的睾丸损伤具有保护作用:结论:补充 HS 的雄性小鼠通过减少氧化应激,减轻了高脂饮食引起的肥胖导致的精液质量差和睾酮水平降低。
{"title":"Hirsutella sinensis intensifies testicular function and spermatogenesis in male mice with high-fat diet-induced obesity.","authors":"Chin-Yu Liu, Chin-Chu Chen, Lynn-Huey Chiang, Bi-Hua Yang, Ting-Chia Chang, Chih-Wei Tsao","doi":"10.1097/JCMA.0000000000001128","DOIUrl":"10.1097/JCMA.0000000000001128","url":null,"abstract":"<p><strong>Background: </strong>Hirsutella sinensis (HS) is a mycelium isolated from the fruiting body of the medicinal mushroom Cordyceps sinensis . This study explored whether HS treatment affects reproductive dysfunction in a high-fat diet (HFD)-induced mouse model and regulates various mechanisms, focusing on oxidative stress, apoptosis, inflammation, and autophagy.</p><p><strong>Methods: </strong>Twenty-four C57BL/6J (B6) mice were randomly divided into a standard chow diet (NCD)- or HFD-fed group for 24 weeks. During the final 8 weeks, half of the HFD-fed mice were orally administered HS (HFD + HS). Biochemical markers, including glucose, insulin, triglycerides, and total cholesterol, were assessed, and hormones, including testosterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH), were analyzed. Liver and testicular histology, as well as sperm quality markers such as sperm motility, sperm count, and percentage of sperm with normal morphology, were observed. The activities of the testicular antioxidants superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) and the products of lipid peroxidation, such as malondialdehyde (MDA), were measured. The protein expression levels of apoptosis-, autophagy- and inflammation-related markers were measured.</p><p><strong>Results: </strong>The HFD-fed mice had abnormal sex hormone levels, poor sperm quality, and a destroyed testicular structure, with increased oxidative stress and apoptosis in the testis. HS supplementation in HFD-fed mice attenuated testicular apoptosis by suppressing the Bax/Bcl-xl ratio and cleaved caspase 3 protein expression. The HS-treated mice exhibited improved reproductive function, possibly due to reduced oxidative stress and apoptosis, suggesting that HS has a protective effect against HFD-induced testicular damage.</p><p><strong>Conclusion: </strong>Male mice supplemented with HS exhibited attenuated poor semen quality and reduced testosterone levels brought about by HFD-induced obesity by reducing oxidative stress.</p>","PeriodicalId":94115,"journal":{"name":"Journal of the Chinese Medical Association : JCMA","volume":" ","pages":"765-773"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of the Chinese Medical Association : JCMA
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1